India Waives Large-Scale Trials For Sanofi’s Dengue Vaccine
This article was originally published in PharmAsia News
Executive Summary
An Indian panel has recommended the government dispense with Phase III trials for Sanofi's vaccine to prevent dengue after last year's major domestic outbreak of the virus caused by the same mosquito responsible for the current spread of Zika disease. The decision comes as India gears up to tackle the new threat from Zika.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.